TBPH’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect?

The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. The metric has seen a significant loss of -26.87% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -19.41%. Over the past 30 days, the price of TBPH has leaped by -18.21%. And in the last five days, it has fallen by -10.26%.

Theravance Biopharma Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $12.03 on 04/17/23, with the lowest value being $8.25 on 02/08/24.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

52-week price history of TBPH Stock

A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Theravance Biopharma Inc’s current trading price is -31.67% away from its 52-week high, while its distance from the 52-week low is -0.36%. The stock’s price range over this timeframe has been between $8.25 and $12.03. The shares of the Healthcare sector company recorded a trading volume of approximately 0.73 million for the day, which was comparatively higher than the average daily volume of 0.4 million over the last three months.

The Connection Between Financial Performance and Market Capitalization

Theravance Biopharma Inc (TBPH) has experienced a quarterly decline of -15.52% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 409.36M and boasts a workforce of 111 employees.

How Moving Averages and Trading Volume Data Work Together

Based on Barchart.com data, the company’s moving average over the 100-day period was 9.88, with a change in price of -0.78. Similarly, Theravance Biopharma Inc recorded 400,004 in trading volume during the last 100 days, posting a change of -8.67%.

TBPH’s Debt-to-Equity Ratio: A Comprehensive Review

A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for TBPH stands at 0.21. Similarly, the long-term debt-to-equity ratio is also 0.17.

TBPH Stock Stochastic Average

Theravance Biopharma Inc’s raw stochastic average for the past 50 days is currently at 0.29%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 0.53%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 8.06% and 9.21%, respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts